Trail­ing the Big Phar­ma play­ers, a less­er known BC­MA CAR-T can­di­date comes in­to the spot­light

Bris­tol My­ers Squibb and blue­bird cleared the first BC­MA CAR-T ther­a­py for mul­ti­ple myelo­ma pa­tients back in March, and J&J and their part­ners at Leg­end Biotech aren’t far be­hind. Now, a less­er known can­di­date de­vel­oped in Chi­na is com­ing in­to the spot­light at EHA.

IBI326, a BC­MA CAR-T ther­a­py de­vel­oped by In­novent Bi­o­log­ics and IA­SO Bio­ther­a­peu­tics, had a 97.1% over­all re­sponse rate in 35 pa­tients with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma, ac­cord­ing to up­dat­ed Phase I da­ta the com­pa­nies are tak­ing to EHA. IA­SO CEO Maxwell Wang says it’s the on­ly oral pre­sen­ta­tion on a Chi­nese BC­MA CAR-T at this year’s con­fer­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.